Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atomoxetine + oxybutynin crossover trial in obstructive sleep apnea
IRCT20220201053905N1Phase 3Completed
- Sponsor
- Tehran University of Medical Sciences
- Start
- Apr 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of atomoxetine and oxybutynin in obstructive sleep apnea hypopnea syndrome (OSAHS) (2 arms), sponsored by Tehran University of Medical Sciences. Primary endpoints: apnea-hypopnea index, apnea index and 7 more. Started Apr 2022; status: completed.
02
Drugs
atomoxetineoxybutynin
03
Conditions
obstructive sleep apnea hypopnea syndrome (OSAHS)
Beyond the preview
Go deeper on IRCT20220201053905N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20220201053905N1.